Table 1.
Clinical features and neuropsychological assessment results of the MS patients and healthy controls.
| MS patients (n = 24) |
Healthy controls (n = 15) |
p-value | |
|---|---|---|---|
| Age (years)a | 38.9 (SD = 11.39) | 44.2 (SD = 10.04) | 0.125 |
| Gender (male:female)b | 8:16 | 8:7 | 0.309 |
| EDSS (expanded disability status scale) | Median = 2.0 (range = 1.0–7.0) | – | – |
| Time from diagnosis (years) | 8.37 (SD = 6.37) | – | – |
| Mean lesion load (n) | 36.2 (range = 5–101) | – | – |
| Current Treatment | |||
|
Interferon beta 1 Natalizumab Teriflunomide Alemtuzumab Fingolimod None |
11 (46%) 1 (4%) 3 (13%) 4 (17%) 3 (13%) 2 (8%) |
– | – |
SD = Standard deviation.
a
Continuous variables were compared with the Mann Whitney U test.
b
Proportions were compared with the chi-square test.